Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
99mTc/188Re-NM-02 in HER2+ Breast Cancer
NCT04674722Phase 1Completed
- Sponsor
- Shanghai General Hospital
- Start
- Aug 2020
- Primary completion
- May 2024
- Modality
- Alpha Emitters, Nanobodies (VHH), Beta Emitters
- Countries
- 1
01
Overview
Phase 1, open-label trial of NM-02 in breast cancer (2 arms), sponsored by Shanghai General Hospital. Primary endpoints: Visual Assessment of HER2 expression in Breast cancer using 99mTc-NM-02 SPECT/CT Scan at 1 year, Semiquantitative Assessment of Breast and other Metastatic Lesions in 99mTc-NM-02 SPECT/CT Scan at 2 years and 3 more. Started Aug 2020; status: completed.
02
Drugs
NM-02
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04674722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04674722.